vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $18.6M, roughly 1.2× ENANTA PHARMACEUTICALS INC). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -64.1%, a 105.5% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
CBK vs ENTA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $18.6M |
| Net Profit | $9.5M | $-11.9M |
| Gross Margin | — | — |
| Operating Margin | — | -60.5% |
| Net Margin | 41.3% | -64.1% |
| Revenue YoY | — | 9.8% |
| Net Profit YoY | 9.7% | 46.4% |
| EPS (diluted) | $0.69 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $18.6M | ||
| Q3 25 | $22.8M | $15.1M | ||
| Q2 25 | — | $18.3M | ||
| Q1 25 | — | $14.9M | ||
| Q4 24 | — | $17.0M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $18.0M |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $-11.9M | ||
| Q3 25 | $9.5M | $-18.7M | ||
| Q2 25 | — | $-18.3M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | — | $-28.8M | ||
| Q2 24 | — | $-22.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | -60.5% | ||
| Q3 25 | 53.8% | -121.6% | ||
| Q2 25 | — | -103.2% | ||
| Q1 25 | — | -164.3% | ||
| Q4 24 | — | -138.8% | ||
| Q3 24 | — | -204.4% | ||
| Q2 24 | — | -134.6% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | -64.1% | ||
| Q3 25 | 41.4% | -123.6% | ||
| Q2 25 | — | -99.7% | ||
| Q1 25 | — | -151.7% | ||
| Q4 24 | — | -131.4% | ||
| Q3 24 | — | -197.3% | ||
| Q2 24 | — | -126.1% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-0.42 | ||
| Q3 25 | $0.77 | $-0.88 | ||
| Q2 25 | — | $-0.85 | ||
| Q1 25 | — | $-1.06 | ||
| Q4 24 | — | $-1.05 | ||
| Q3 24 | — | $-1.36 | ||
| Q2 24 | — | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $37.4M |
| Total DebtLower is stronger | $118.2M | — |
| Stockholders' EquityBook value | — | $126.6M |
| Total Assets | $2.3B | $329.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $37.4M | ||
| Q3 25 | $154.8M | $32.3M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $60.2M | ||
| Q4 24 | — | $84.3M | ||
| Q3 24 | — | $37.2M | ||
| Q2 24 | — | $35.8M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $126.6M | ||
| Q3 25 | $245.2M | $64.7M | ||
| Q2 25 | — | $79.3M | ||
| Q1 25 | — | $93.5M | ||
| Q4 24 | — | $111.8M | ||
| Q3 24 | — | $128.8M | ||
| Q2 24 | — | $148.9M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $329.5M | ||
| Q3 25 | $2.2B | $280.7M | ||
| Q2 25 | — | $301.0M | ||
| Q1 25 | — | $323.0M | ||
| Q4 24 | — | $348.6M | ||
| Q3 24 | — | $376.7M | ||
| Q2 24 | — | $398.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-11.7M |
| Free Cash FlowOCF − Capex | — | $-11.8M |
| FCF MarginFCF / Revenue | — | -63.6% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-11.7M | ||
| Q3 25 | $28.0M | $-6.5M | ||
| Q2 25 | — | $17.5M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | — | $-16.8M | ||
| Q3 24 | — | $-10.4M | ||
| Q2 24 | — | $-14.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-11.8M | ||
| Q3 25 | $26.5M | $-7.9M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $-16.0M | ||
| Q4 24 | — | $-25.5M | ||
| Q3 24 | — | $-19.4M | ||
| Q2 24 | — | $-21.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | -63.6% | ||
| Q3 25 | 115.8% | -52.5% | ||
| Q2 25 | — | 94.7% | ||
| Q1 25 | — | -107.4% | ||
| Q4 24 | — | -150.6% | ||
| Q3 24 | — | -132.5% | ||
| Q2 24 | — | -118.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.8% | ||
| Q3 25 | 6.7% | 9.6% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | — | 51.6% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 36.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
ENTA
Segment breakdown not available.
